Lumena Files For $75 Million IPO To Forward Liver Disease Drugs
This article was originally published in The Pink Sheet Daily
Biotech investment momentum may have slowed recently, but the San Diego biotech is hoping the IPO window remains open. The company is developing a compound shelved by Pfizer to address high cholesterol; LUM001 currently is in Phase II for a set of cholestatic liver diseases.
You may also be interested in...
The San Diego start-up will use its Series A round to continue development on a pair of drugs for cholestatic liver disease. Once studied by Pfizer and Sanofi to fight high cholesterol but shelved years ago as statins proved more effective, the drugs show promise in orphan indications.
Cosmetics companies that disclose the presence of PFAS in their products and explain measures they are taking to minimize PFAS’ presence are better protected from lawsuits, says Dentons US attorney Michael Duvall.
Pharma-related regulatory issues are dominant in the latest annual White Paper from the EU Chamber of Commerce in Korea, accounting for 22 of the 96 concerns raised across 18 industries that will be shared with ministries. Quality of life issues around drugs for chronic disorders, risk-sharing agreements, reimbursement and vaccine policies are some of the key questions raised.